This is a video synopsis/summary of a panel discussion involving Linda Stein Gold, MD; Mona Shahriari, MD, FAAD; and Seemal Desai, MD.
In this conversation on the impact of psoriasis in patients with skin of color, the participants highlight the significant burden the disease carries, particularly from a quality of life perspective. They note the cultural stigma associated with skin conditions, which can lead to isolation and emotional distress for affected individuals.
The speakers emphasize the importance of understanding the unique challenges faced by patients with skin of color, including the psychological impact of post-inflammatory changes and dyspigmentation. They advocate for a compassionate approach and early consideration of systemic medications to prevent long-term pigmentary sequelae.
They discuss the cultural significance of visible skin conditions, such as psoriasis on the hands or face, within certain communities. He stresses the role of dermatologists in addressing not only the physical symptoms but also the social and cultural implications of the disease.
The conversation underscores the need for culturally competent care and emphasizes the importance of listening to patients' experiences and concerns. By acknowledging and addressing the impact of psoriasis on both physical and emotional well-being, healthcare providers can better support patients in managing their condition and improving their overall quality of life.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
Social and Cultural Stigma of Psoriasis in Patients With Skin of Color
Mona Shahriari, MD, FAAD
Drs Stein Gold, Shahriari and Desai highlight social and cultural stigma of psoriasis in patients with skin of color and its impact on patient’s quality of life.
EP: 1.Presentation of and Challenges in Treatment of Psoriasis in Patients With Skin of Color
EP: 2.Social and Cultural Stigma of Psoriasis in Patients With Skin of Color
EP: 3.Communicating With Patients With Psoriasis With Skin of Color
EP: 4.Post-Inflammatory Dyspigmentation in Patients With Skin of Color
EP: 5.Topical Treatments for Psoriasis for Patients With Skin of Color
EP: 6.Traditional Systemic Therapy for Psoriasis for Patients With Skin of Color
EP: 7.Guselkumab in Patients With Skin of Color: VISIBLE Trial Design
EP: 8.Results of VISIBLE Trial in Patients With Skin of Color
EP: 9.Early Use of Systemic Treatments in Patients With Skin of Color
EP: 10.Data With Biologics in Patients With Skin of Color
EP: 11.Advice for Dermatologists in Treating Psoriasis in Patients With Skin of Color
This is a video synopsis/summary of a panel discussion involving Linda Stein Gold, MD; Mona Shahriari, MD, FAAD; and Seemal Desai, MD.
In this conversation on the impact of psoriasis in patients with skin of color, the participants highlight the significant burden the disease carries, particularly from a quality of life perspective. They note the cultural stigma associated with skin conditions, which can lead to isolation and emotional distress for affected individuals.
The speakers emphasize the importance of understanding the unique challenges faced by patients with skin of color, including the psychological impact of post-inflammatory changes and dyspigmentation. They advocate for a compassionate approach and early consideration of systemic medications to prevent long-term pigmentary sequelae.
They discuss the cultural significance of visible skin conditions, such as psoriasis on the hands or face, within certain communities. He stresses the role of dermatologists in addressing not only the physical symptoms but also the social and cultural implications of the disease.
The conversation underscores the need for culturally competent care and emphasizes the importance of listening to patients' experiences and concerns. By acknowledging and addressing the impact of psoriasis on both physical and emotional well-being, healthcare providers can better support patients in managing their condition and improving their overall quality of life.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
Sleep of Psoriasis Patients Improves with Intensive Topical Treatment
April 24th 2024A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis
February 28th 2024Study Details Epitope Binding, Efficacy of IL-23 Inhibitors in Plaque Psoriasis
April 24th 2024Considering Safety of IL-23 Inhibitors for Plaque Psoriasis With The Patient
November 17th 2023Psoriasis Severity Index Scores Impacted by Tobacco Smoking in Current, Former Smokers
April 16th 2024Guselkumab Led to Improvements in Psoriasis Symptoms, Decreased Sexual Impairment
April 12th 2024Sleep of Psoriasis Patients Improves with Intensive Topical Treatment
April 24th 2024A Patient-Centric Medcast on the Journey Through Moderate Plaque Psoriasis
February 28th 2024Study Details Epitope Binding, Efficacy of IL-23 Inhibitors in Plaque Psoriasis
April 24th 2024Considering Safety of IL-23 Inhibitors for Plaque Psoriasis With The Patient
November 17th 2023Psoriasis Severity Index Scores Impacted by Tobacco Smoking in Current, Former Smokers
April 16th 2024Guselkumab Led to Improvements in Psoriasis Symptoms, Decreased Sexual Impairment
April 12th 2024